216 related articles for article (PubMed ID: 27128712)
1. Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.
Liang S; Brundage RC; Jacobson PA; Blaes A; Kirstein MN
Br J Clin Pharmacol; 2016 Sep; 82(3):773-83. PubMed ID: 27128712
[TBL] [Abstract][Full Text] [Related]
2. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
4. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
[TBL] [Abstract][Full Text] [Related]
5. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
Rüger AM; Schneeweiss A; Seiler S; Tesch H; van Mackelenbergh M; Marmé F; Lübbe K; Sinn B; Karn T; Stickeler E; Müller V; Schem C; Denkert C; Fasching PA; Nekljudova V; Garfias-Macedo T; Hasenfuß G; Haverkamp W; Loibl S; von Haehling S
J Am Heart Assoc; 2020 Dec; 9(23):e018143. PubMed ID: 33191846
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
8. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
9. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
10. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
[TBL] [Abstract][Full Text] [Related]
11. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer.
D'Errico MP; Grimaldi L; Petruzzelli MF; Gianicolo EA; Tramacere F; Monetti A; Placella R; Pili G; Andreassi MG; Sicari R; Picano E; Portaluri M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e239-46. PubMed ID: 21640499
[TBL] [Abstract][Full Text] [Related]
12. Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).
Bhatt AS; Cooper LB; Ambrosy AP; Clare RM; Coles A; Joyce E; Krishnamoorthy A; Butler J; Felker GM; Ezekowitz JA; Armstrong PW; Hernandez AF; O'Connor CM; Mentz RJ
J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29431103
[TBL] [Abstract][Full Text] [Related]
13. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism.
Binder L; Pieske B; Olschewski M; Geibel A; Klostermann B; Reiner C; Konstantinides S
Circulation; 2005 Sep; 112(11):1573-9. PubMed ID: 16144990
[TBL] [Abstract][Full Text] [Related]
14. The utility of NT-proBNP and various echocardiographic methods in the determination of doxorubicin induced subclinical late cardiotoxicity.
Yildirim A; Tunaoglu FS; Kambur K; Pinarli FG
Kardiol Pol; 2013; 71(1):40-6. PubMed ID: 23348532
[TBL] [Abstract][Full Text] [Related]
15. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
16. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
[TBL] [Abstract][Full Text] [Related]
17. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
Clin Chem; 2010 Nov; 56(11):1718-24. PubMed ID: 20844063
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department.
Gaggin HK; Chen-Tournoux AA; Christenson RH; Doros G; Hollander JE; Levy PD; Nagurney JT; Nowak RM; Pang PS; Patel D; Peacock WF; Walters EL; Januzzi JL;
Am Heart J; 2017 Oct; 192():26-37. PubMed ID: 28938961
[TBL] [Abstract][Full Text] [Related]
19. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
20. Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer.
Silva FB; Romero WG; Carvalho AL; Borgo MV; Amorim MH; Gouvea SA; Abreu GR
Braz J Med Biol Res; 2015 Feb; 48(2):154-60. PubMed ID: 25424369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]